-$0.50 Earnings Per Share Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter

Wall Street analysts forecast that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce earnings of ($0.50) per share for the current quarter, Zacks reports. Four analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.53) and the highest estimate coming in at ($0.44). Syros Pharmaceuticals posted earnings of ($0.58) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.8%. The company is scheduled to announce its next quarterly earnings results on Monday, March 11th.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full year earnings of ($1.86) per share for the current year, with EPS estimates ranging from ($1.92) to ($1.77). For the next financial year, analysts forecast that the company will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.12) to ($1.67). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, November 1st. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.02). The business had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.72 million.

Several equities research analysts have commented on SYRS shares. BidaskClub raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 31st. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Cann reaffirmed a “buy” rating and issued a $26.00 price target on shares of Syros Pharmaceuticals in a report on Tuesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Tuesday, July 17th. Finally, Roth Capital raised shares of Syros Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $19.00.

Large investors have recently bought and sold shares of the business. Wedge Capital Management L L P NC purchased a new stake in shares of Syros Pharmaceuticals during the 3rd quarter worth about $731,000. Alps Advisors Inc. boosted its stake in shares of Syros Pharmaceuticals by 26.0% during the 3rd quarter. Alps Advisors Inc. now owns 59,553 shares of the company’s stock worth $709,000 after acquiring an additional 12,280 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Syros Pharmaceuticals by 52.2% during the 2nd quarter. Northern Trust Corp now owns 275,638 shares of the company’s stock worth $2,814,000 after acquiring an additional 94,548 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Syros Pharmaceuticals by 36.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,592 shares of the company’s stock worth $720,000 after acquiring an additional 19,005 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Syros Pharmaceuticals by 129.3% during the 2nd quarter. Millennium Management LLC now owns 375,466 shares of the company’s stock worth $3,834,000 after acquiring an additional 211,696 shares in the last quarter. 60.74% of the stock is currently owned by institutional investors.

NASDAQ:SYRS opened at $8.06 on Wednesday. Syros Pharmaceuticals has a one year low of $6.25 and a one year high of $15.88. The firm has a market capitalization of $261.16 million, a price-to-earnings ratio of -3.78 and a beta of 0.78.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Further Reading: Dollar Cost Averaging

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply